The story doesnt end with decreased spending, however
Also delivery.Brittany D.Trustindex verifies that the original source of the review is Google.LOVE LOVE LOVE this place
Veldhorst MA, Westerterp-Plantenga MS, Westerterp KR
This is about saving hearts Who qualifies: Adults with established CVD + overweight/obesity (BMI 27 kg/m) The drug: Semaglutide 2.4mg once-weekly subcutaneous injection (GLP-1 RA) Titrated to maintenance dose Adjunct to lifestyle counselling & standard care Why NICE said yes: Reduces risk of MACE (heart attack, stroke, CV death) in this population Cost-effective within NHS thresholds (20,00030,000/QALY) Commercial agreement already in place with NHS The pathway is simple: Assess CVD risk Lifestyle counselling Add semaglutide Monitor This follows SELECT trial data showing ~20% MACE reduction independent of weight loss We are watching GLP-1s redefine cardiovascular medicine in real time From diabetes obesity now primary CV risk reduction Whats next
However, maintaining open communication with healthcare providers about any unusual symptoms ensures appropriate evaluation and continued safe use of this effective therapeutic agent
The IWQOL-Lite-CT is a shorter version of the 74-item Impact of Weight on Quality of Life (IWQOL), an instrument that was developed to assess HRQoL specifically in patients living with moderate to severe obesity
